Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting

6/18/24 9:29:47 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ACAD alert in real time by email

Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide).

Get the next $ACAD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ACAD

Date	Price Target	Rating	Analyst
10/10/2024		Mkt Perform	Raymond James
8/7/2024	$28.00 → $20.00	Overweight → Equal-Weight	Morgan Stanley
6/27/2024	$31.00	Outperform	BMO Capital Markets
3/12/2024	$36.00 → $32.00	Buy	Needham
3/12/2024	$39.00 → $25.00	Buy → Neutral	Mizuho
1/30/2024	$40.00	Outperform	Robert W. Baird
1/24/2024	$37.00	Hold → Buy	Needham
12/19/2023	$31.00 → $40.00	Equal-Weight → Overweight	Morgan Stanley

More analyst ratings

$ACAD
Press Releases

Fastest customizable press release news feed in the world

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore HealthCONx Conference Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL Live webcasts of each fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience
11/21/24 4:05:00 PM ET
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units ("RSUs") to twenty-three new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $17.66 per share, Acadia's closing trading price on November 8, 2024, and will vest over four years,
11/15/24 4:05:00 PM ET
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
- 3Q24 total revenues of $250.4 million, up 18% year-over-year - 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year - 3Q24 DAYBUE™ (trofinetide) net product sales of $91.2 million, up 36% year-over-year Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the third quarter ended September 30, 2024. "The success of Acadia's two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive milestone of more than $1 billion in annualized sales in 2025," said Catherine Owen Adams, Chief Executive Officer.
11/6/24 4:05:00 PM ET
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care

$ACAD
Leadership Updates

Live Leadership Updates

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
- Ms. Owen Adams brings over 25 years of pharmaceutical industry experience including senior commercial leadership roles with Bristol Myers Squibb and Johnson & Johnson Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. "We are excited to welcome Catherine Owen Adams as the new CEO of Acadia," said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. "Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical industry. Her strategic vision, deep expertise, and unwavering
9/23/24 4:15:00 PM ET
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company's Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia. "Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercialization of first in class therapies," said Steve Davis, Chief Executive Officer. "Her passion and expertise for developing new medicines that address areas of high unmet need will be a huge asset to Acadia and an important add
4/2/24 4:05:00 PM ET
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company's Executive Management Committee. He will report to Mark Schneyer, Executive Vice President, Chief Financial Officer of Acadia. "Al brings to Acadia a strong track record of leading investor relations and corporate communications functions at numerous growth-oriented companies across the healthcare industry," said Mark Schneyer, Executive Vice President, Chief Financial Officer. "His deep experienc
9/19/23 4:05:00 PM ET
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
- 3Q24 total revenues of $250.4 million, up 18% year-over-year - 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year - 3Q24 DAYBUE™ (trofinetide) net product sales of $91.2 million, up 36% year-over-year Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the third quarter ended September 30, 2024. "The success of Acadia's two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive milestone of more than $1 billion in annualized sales in 2025," said Catherine Owen Adams, Chief Executive Officer.
11/6/24 4:05:00 PM ET
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
Company to host conference call and webcast on Wednesday, November 6, 2024, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived there until December 6, 2024. The conference call may also be accessed by registering for the call here. Once registered, par
10/17/24 6:41:00 PM ET
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
- Second quarter total net product sales of $242.0 million, up 46% year-over-year Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the second quarter ended June 30, 2024. "In the second quarter of 2024, Acadia delivered $242.0 million in net product sales, highlighted by 11% year-over-year growth in NUPLAZID net sales and 11% sequential growth in DAYBUE net sales," said Steve Davis, Chief Executive Officer. "Additionally, we are advancing enrollment in our Phase 3 trial in Prader-Willi syndrome and our Phase 2 / Phase 3 program in Alzheimer's disease psychosis. With two successful commercial products, a strong pipeline of late and early-stage assets an
8/6/24 4:05:00 PM ET
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care

Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting

Chat with this insight

Recent Analyst Ratings for $ACAD

$ACAD Press Releases

Fastest customizable press release news feed in the world

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

$ACAD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

FDA Approval for DAYBUE issued to ACADIA PHARMS INC

$ACAD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, COO, HEAD OF COMMERCIAL Teehan Brendan converted options into 19,826 shares and sold $173,630 worth of shares (10,329 units at $16.81), increasing direct ownership by 18% to 62,105 units (SEC Form 4)

PRINCIPAL ACCOUNTING OFFICER Kihara James converted options into 7,930 shares and sold $68,467 worth of shares (4,073 units at $16.81), increasing direct ownership by 24% to 19,863 units (SEC Form 4)

EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. converted options into 19,826 shares and sold $172,454 worth of shares (10,259 units at $16.81), increasing direct ownership by 22% to 53,302 units (SEC Form 4)

$ACAD Leadership Updates

Live Leadership Updates

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

$ACAD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James resumed coverage on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals downgraded by Morgan Stanley with a new price target

BMO Capital Markets initiated coverage on ACADIA Pharmaceuticals with a new price target

$ACAD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

SEC Form SC 13G filed by ACADIA Pharmaceuticals Inc.

SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

$ACAD SEC Filings

SEC Form 8-K filed by ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form S-8 filed by ACADIA Pharmaceuticals Inc.

$ACAD Financials

Live finance-specific insights

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

$ACAD Market Insights

Live Market Insights

A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals

Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $28

Recent Analyst Ratings for
$ACAD

$ACAD
Press Releases

$ACAD
FDA approvals

$ACAD
Insider Trading

$ACAD
Leadership Updates

$ACAD
Analyst Ratings

$ACAD
Large Ownership Changes

$ACAD
SEC Filings

$ACAD
Financials

$ACAD
Market Insights